Sept 24 (Reuters) - China's Jiangsu Hengrui Pharmaceuticals (600276.SS), opens new tab said on Wednesday it has agreed to grant a paid license for its innovative cancer drug trastuzumab rezetecan to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results